Dopaminergic system does not play a major role in the precipitated cannabinoid withdrawal syndrome

Acta Pharmacologica Sinica

Volumn 20, Issue 12, 1999, Pages 1121-1124

  Sañudo Peña, M Clara ^a   Force, Michelle ^a   Kang, Tsou ^a   McLemore, Gabrielle ^a   Roberts, Langdon ^a   Walker, J Michael ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Cannabinoids; Dopamine antagonists; Dopamine D1 receptors; Dopamine D2 receptors; Pain; Pruritus; SR141716A; Substance withdrawal syndrome; Tetrahydrocannabinol

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CANNABINOID; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DRONABINOL; RIMONABANT; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CANNABIS ADDICTION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PAIN; PRURITUS; RAT; WITHDRAWAL SYNDROME;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; CANNABINOIDS; DOPAMINE ANTAGONISTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL;

EID: 0032761241     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Tsou K, Patrick SL, Walker JM. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 1995; 280: R13-5.
2. Aceto MD, Scates SM, Lowe JA, Martin BR. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 1995; 282: R1-2.
3. McMillan DE, Dewey WL, Harris LS. Characteristics of tetrahydrocannabinol tolerance. Ann N Y Acad Sci 1971; 91: 83-6.
4. Wall ME, Sadler BM, Brine D, Taylor H, Percz-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983; 34: 352-63.
5. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
6. Aceto MD, Scales SM, Lowe JA, Martin BR. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 1996; 278: 1290-5.
7. Diana M, Melis M, Muntoni AL, Gessa GL. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 1998; 95: 10269-73.
8. Rubino T, Patrini G, Massi P, Fuzio D, Vigano D, Giagnoni G, et al. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 1998; 285: 813-9.
9. Diana M, Muntoni AL, Pistis M, Melis M, Gessa GL. Lasting reduction in mesolimbic dopamine neuronal activity after morphine withdrawal. Eur J Neurosci 1999; 3: 1037-41.
10. Summerfield JA. Pain, itch, and endorphins. Br J Dermatol 1981; 105: 725-6.
11. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997; 319: R3-4.
12. 2 agonists in squirrel monkeys. J Pharmacol Exp Ther 1995; 273: 138-45.